Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Corporate Update (July 2019)

18 slides from Marinus Pharmaceuticals's corporate update, Jul 23, 2019

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private

  2. Slide 2: Marinus PPD Development Program with Ganaxolone

    Marinus PPD Development Program with Ganaxolone 3 Part 1 Part 2 48-hour IV + 12-hour taper 6-hour IV + 900mg oral + Oral 675mg Oral 675mg/BID for 2 days then 1125 mg for 26 days Early onset of action Good safety Attractive efficacy Low Dose High Dose

  3. Slide 3: PPD Market Segmentation and Value

    Total Annual U.S. PPD Prevalence* ~550K Patients (100%) PPD Market Segmentation and Value *PPD prevalence estimated at ~13% of total 2018 live births of 4.1MM – RBC Analyst report 10/18/18 4 Mild PPD Moderate PPD Severe PPD 10% - 20% of moderate and severe PPD patients require hospitalization

  4. Slide 4: Magnolia Study - Part 1 Results (December 2018)

    Magnolia Study - Part 1 Results (December 2018) 5 Evaluate safety, tolerability, PK & efficacy of three exposure levels of ganaxolone IV in women with PPD n = 58 Ganaxolone IV 60 µg/kg/h Placebo IV Double blind R1:1 Follow-up: Day 11, Day 34 Ganaxolone IV 140 µg/kg/h 48-hours + 12-hour taper Ganaxol

  5. Slide 5: Patient Disposition and Baseline Characteristics

    Patient Disposition and Baseline Characteristics 6 Baseline Characteristics Placebo (n=17) GNX (n=16) CHARACTERISTICS n (%) n (%) Age (years) [mean (SD)] 24.9 (5.1) 28.8 (5.0) Race Black of African-American 12 (70.6) 8 (50) White 4 (23.5) 8 (50) Other 1 (5.9) 0 (0) Pre-partum onset of depression 3 (

  6. Slide 6: Magnolia Study – Part 2 Trial Design

    Trial Details Evaluate safety, tolerability and efficacy of ganaxolone IV to oral 6 US sites Multi-cohort, IV to oral administration HAM-D baseline: GNX 26.6 PBO 26.4 Magnolia Study – Part 2 Trial Design 7 N=17 Placebo n = 33 Double blind R1:1 Ganaxolone Oral (900 mg/daily) Ganaxolone IV (20 mg/hr)

  7. Slide 7: Efficacy Results: HAM-D17 Mean Change from Baseline

    Efficacy Results: HAM-D17 Mean Change from Baseline 8 HAM-D17 Mean Change from Baseline Per Protocol Population Ganaxolone Placebo Ganaxolone Placebo HAM-D17 Mean Change from Baseline ITT Population 𝚫 – 2.8 𝚫 – 2.6 𝚫 -3.4 𝚫 -2.7 𝚫 + 1.0 𝚫 – 2.6 Least-squares (LS) mean reductions reported 6h…

  8. Slide 8: Efficacy Results: CGI-I Mean Change from Baseline

    CGI-I Score Per Protocol Population CGI-I Score ITT Population Efficacy Results: CGI-I Mean Change from Baseline 9 Ganaxolone Placebo Ganaxolone Placebo Least-squares (LS) mean reductions reported 7 days 14 days 21 days 28 days 24 hours 6 hours 7 days 14 days 21 days 28 days 24 hours 6 hours

  9. Slide 9: HAM-D17 Response and Remission Rates - ITT Population

    HAM-D17 Response and Remission Rates - ITT Population 10 Remission: HAM-D17 > 7 points Ganaxolone Placebo Ganaxolone Placebo n = 17 n = 16 n = 16 n = 13 n = 14 n = 15 n = 17 n = 16 n = 16 n = 13 n = 14 n = 15 Response: HAM-D17 decrease > 50% HAM-D17 Response Rates HAM-D17 Remission Rates 14 days 28

  10. Slide 10: HAM-D17 Response and Remission - Per Protocol Population

    HAM-D17 Response and Remission - Per Protocol Population 11 n = 13 n = 15 n = 12 n = 12 n = 10 n = 14 Ganaxolone Placebo n = 13 n = 15 n = 12 n = 12 n = 10 n = 14 Ganaxolone Placebo Response: HAM-D17 decrease > 50% Remission: HAM-D17 > 7 points 14 days 28 days 24 hours 14 days 28 days 24 hours HAM-D

  11. Slide 11: CGI-I Response Rates

    CGI-I Response Rates 12 Ganaxolone Placebo n = 17 n = 16 n = 16 n = 14 n = 13 n = 15 n = 14 n = 15 n = 13 n = 13 n = 11 n = 14 Ganaxolone Placebo 14 days 28 days 24 hours 14 days 28 days 24 hours ITT Population Per Protocol Population

  12. Slide 12: Tolerability and Safety

    Tolerability and Safety 13 Dizziness Somnolence Sedation TEAE Placebo n (%) Ganaxolone n (%) Dizziness 1 Mod (6) 4 Mod (25) Sedation 1 Mild (6) 1 Mod (6) Somnolence 1 Mild (6) 1 Mild 3 Mod (25) DC for AE 0 0 SAE 1 (suicide attempt) 0 Dose Reduction 1Dizziness (6) 2 Dizziness (12) 1 headache (6) 1 so

  13. Slide 13: Amaryllis – Ganaxolone Oral for PPD

    Amaryllis – Ganaxolone Oral for PPD Evaluate safety, tolerability, PK and efficacy of oral ganaxolone in women with PPD 14 Ganaxolone Oral (675 mg/daily) 4 Weeks Low Dose High Dose Day 1-2 n = 43 Ganaxolone Oral (675 mg at dinner & bedtime) Ganaxolone Oral (1,125 mg/daily) Day 3 - 28 n = 25 Baseline

  14. Slide 14: Amaryllis – Change from Baseline in HAM-D17 Score

    Amaryllis – Change from Baseline in HAM-D17 Score 15 Day 2 Day 15 Day 29 Low dose (675mg) 0.8 9.8 12.2 High dose (1125mg) 2.7 9.3 14.5 Generally safe and well tolerated No SAEs or discontinuations due to TRAEs No syncope or loss of consciousness

  15. Slide 15: Ganaxolone in PPD: Conclusions / Next Steps

    Ganaxolone in PPD: Conclusions / Next Steps 16 Magnolia Part 2 data: ganaxolone administered as 6-hour infusion provided rapid onset of activity with clinically meaningful reductions in HAM-D scores at the early time points of 6 hours and 24 hours of treatment. Second proof-of-concept for the therap

  16. Slide 16: Q&A

    Magnolia Part 2: (Top Line) Clinical Data Jess, change illustration Q&A

  17. Slide 17: Thank You

    Magnolia Part 2: (Top Line) Clinical Data Jess, change illustration Thank You

  18. Slide 18: Thank You

    Thank You M'ARINUS PHARMACEUTICALS

Marinus Pharmaceuticals — Corporate Update (July 2019) on 6ix